Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIOGEN INC.

(BIIB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
262.8(c) 266.19(c) 265.79(c) 270.44(c) 270.31(c) Last
753 596 823 301 697 428 986 472 999 778 Volume
-2.00% +1.29% -0.15% +1.75% -0.05% Change
More quotes
Financials (USD)
Sales 2021 10 563 M - -
Net income 2021 2 303 M - -
Net Debt 2021 1 289 M - -
P/E ratio 2021 17,6x
Yield 2021 -
Sales 2022 10 593 M - -
Net income 2022 2 583 M - -
Net cash position 2022 462 M - -
P/E ratio 2022 15,0x
Yield 2022 -
Capitalization 40 696 M 40 696 M -
EV / Sales 2021 3,97x
EV / Sales 2022 3,80x
Nbr of Employees 9 100
Free-Float 85,9%
More Financials
Company
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment... 
Sector
Pharmaceuticals
Calendar
04/22Earnings Release
More about the company
Notations Surperformance© of Biogen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about BIOGEN INC.
04/17BIOGEN  : Aducanumab EMBARK study design poster at AAN 2021
PU
04/16BIOGEN  : Grows Presence in China with the Approval of TECFIDERA (dimethyl fumar..
AQ
04/16New Data at AAN 2021 from Across Biogen's MS Portfolio Demonstrate Positive I..
GL
04/15BIOGEN  : Wins Regulatory Approval in China for Tecfidera for Multiple Sclerosis
MT
04/15STREET COLOR : Biogen Reportedly Receives Regulatory Nod in China for Relapsing ..
MT
04/15BIOGEN  : Grows Presence in China with the Approval of TECFIDERA® (dimethyl fuma..
AQ
04/15Biogen Says Tecfidera Approved in China to Treat Relapsing Multiple Sclerosis
DJ
04/15BIOGEN  : to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster..
AQ
04/14BIOGEN  : Drug Updates of Particular Interest as Investors Await Q1 Results, Miz..
MT
04/14Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster..
GL
04/12BIOGEN  : Wedbush Adjusts Price Target on Biogen to $245 From $236, Maintains Ne..
MT
04/12SAGE THERAPEUTICS  : Biogen Drug Candidate's Phase 2 Study in Essential Tremor M..
MT
04/12Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatme..
DJ
04/12BIOGEN  : Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Control..
BU
04/09BIOGEN INC.  : Change in Directors or Principal Officers, Financial Statements a..
AQ
More news
News in other languages on BIOGEN INC.
04/07Wall Street : pause dans une tendance demeurant très positive
04/06Wall Street : pause dans une tendance demeurant très positive
03/30Trois entreprises selon les critères de Warren Buffett
03/19EEUU aprueba el tratamiento de la esclerosis múltiple de J&J, que se lanzará ..
03/16Wall Street : bon début de semaine en attendant la Fed
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 34
Average target price 291,50 $
Last Close Price 270,31 $
Spread / Highest target 69,4%
Spread / Average Target 7,84%
Spread / Lowest Target -38,6%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.10.45%40 696
CSL LIMITED-4.98%94 687
WUXI BIOLOGICS (CAYMAN) INC.2.14%56 894
SAMSUNG BIOLOGICS CO.,LTD.0.61%49 298
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.18.65%43 060
ALEXION PHARMACEUTICALS, INC.4.76%35 962